echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Zhong Nanshan: China's new crown drugs are valuable for promotion worldwide

    Zhong Nanshan: China's new crown drugs are valuable for promotion worldwide

    • Last Update: 2021-12-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Experts introduced the effects of the approved new coronavirus neutralizing antibody combination therapy drugs "Ambasvirimab Injection and Romisvirimab Injection"
    .
    However, the pace of mutation of the new coronavirus has not stopped.
    Can the drug resist the mutated virus? Will there be side effects after using the drug?
     
    Zhong Nanshan, an academician of the Chinese Academy of Engineering, presided over the Phase II clinical study of the drug in China, and took the lead in demonstrating and promoting the emergency treatment of the drug in China, further verifying the safety and effectiveness of the drug in Chinese patients
    .
     
    Zhong Nanshan, Academician of the Chinese Academy of Engineering: BRII-196, 198 (ampavirimab and romisvirimab) antibodies are very effective for the treatment of patients with a large viral load.
    So far, it should be said that this is the most effective
    .
    China can produce a drug developed by its own design on the antibody, it is very valuable, including the drug itself after a lot of antibody screening, so I think the promotion of this drug in the world is very valuable Of
    .
     
    It is reported that the Guangzhou laboratory team led by Academician Zhong Nanshan is presided over the research work of the drug for prevention, and promotes the preventive use of people with poor vaccine response
    .
     
      Zhong Nanshan, academician of the Chinese Academy of Engineering: If it (medicine) costs very high, prevention is not realistic
    .
    But at least until now, I think we should see some poor immune function (the crowd), such as whether it is heavier chronic heart disease, chronic obstructive pulmonary disease, liver disease, first with the antibody in advance, there may be good The preventive effect
    .
     
      According to reports, these two drugs can be used in combination to treat mild and common adults and adolescents with new coronavirus infections who are accompanied by high risk factors for progression to severe
    .
    Are there any side effects after the drug is used? Academician Zhong Nanshan also gave the answer
    .
     
      On December 12, Tengshengbo Pharmaceutical issued an announcement.
    The data shows that the approved drugs are against Omi Keron and other widely concerned new coronavirus variants including Alpha, Beta, Gamma, Delta, Delta+, etc.
    Maintained its effectiveness
    .
    Zhang Qi, an assistant researcher at the School of Medicine of Tsinghua University, who participated in the research and development, said that there may be more mutations in the virus, but researchers are already prepared
    .
     
      Zhang Qi, assistant researcher at the School of Medicine of Tsinghua University: We have also felt some patterns, because the mutant strain is always mutating.
    We can’t say what Omi Keron will come out today, and what will come out tomorrow.
    We are always chasing after it.
    We have to To prepare in advance, we have been studying where the changes of mutant strains are to deal with possible mutations in the future
    .
      Experts introduced the effects of the approved new coronavirus neutralizing antibody combination therapy drugs "Ambasvirimab Injection and Romisvirimab Injection"
    .
    However, the pace of mutation of the new coronavirus has not stopped.
    Can the drug resist the mutated virus? Will there be side effects after using the drug?
     
      Zhong Nanshan, an academician of the Chinese Academy of Engineering, presided over the Phase II clinical study of the drug in China, and took the lead in demonstrating and promoting the emergency treatment of the drug in China, further verifying the safety and effectiveness of the drug in Chinese patients
    .
     
      Zhong Nanshan, Academician of the Chinese Academy of Engineering: BRII-196, 198 (ampavirimab and romisvirimab) antibodies are very effective for the treatment of patients with a large viral load.
    So far, it should be said that this is the most effective
    .
    China can produce a drug developed by its own design on the antibody, it is very valuable, including the drug itself after a lot of antibody screening, so I think the promotion of this drug in the world is very valuable Of
    .
     
      It is reported that the Guangzhou laboratory team led by Academician Zhong Nanshan is presided over the research work of the drug for prevention, and promotes the preventive use of people with poor vaccine response
    .
     
      Zhong Nanshan, academician of the Chinese Academy of Engineering: If it (medicine) costs very high, prevention is not realistic
    .
    But at least until now, I think we should see some poor immune function (the crowd), such as whether it is heavier chronic heart disease, chronic obstructive pulmonary disease, liver disease, first with the antibody in advance, there may be good The preventive effect
    .
     
      According to reports, these two drugs can be used in combination to treat mild and common adults and adolescents with new coronavirus infections who are accompanied by high risk factors for progression to severe
    .
    Are there any side effects after the drug is used? Academician Zhong Nanshan also gave the answer
    .
     
      On December 12, Tengshengbo Pharmaceutical issued an announcement.
    The data shows that the approved drugs are against Omi Keron and other widely concerned new coronavirus variants including Alpha, Beta, Gamma, Delta, Delta+, etc.
    Maintained its effectiveness
    .
    Zhang Qi, an assistant researcher at the School of Medicine of Tsinghua University, who participated in the research and development, said that there may be more mutations in the virus, but researchers are already prepared
    .
     
      Zhang Qi, assistant researcher at the School of Medicine of Tsinghua University: We have also felt some patterns, because the mutant strain is always mutating.
    We can’t say what Omi Keron will come out today, and what will come out tomorrow.
    We are always chasing after it.
    We have to To prepare in advance, we have been studying where the changes of mutant strains are to deal with possible mutations in the future
    .
      Experts introduced the effects of the approved new coronavirus neutralizing antibody combination therapy drugs "Ambasvirimab Injection and Romisvirimab Injection"
    .
    However, the pace of mutation of the new coronavirus has not stopped.
    Can the drug resist the mutated virus? Will there be side effects after using the drug?
     
      Zhong Nanshan, an academician of the Chinese Academy of Engineering, presided over the Phase II clinical study of the drug in China, and took the lead in demonstrating and promoting the emergency treatment of the drug in China, further verifying the safety and effectiveness of the drug in Chinese patients
    .
     
      Zhong Nanshan, Academician of the Chinese Academy of Engineering: BRII-196, 198 (ampavirimab and romisvirimab) antibodies are very effective for the treatment of patients with a large viral load.
    So far, it should be said that this is the most effective
    .
    China can produce a drug developed by its own design on the antibody, it is very valuable, including the drug itself after a lot of antibody screening, so I think the promotion of this drug in the world is very valuable Of
    .
     
      It is reported that the Guangzhou laboratory team led by Academician Zhong Nanshan is presided over the research work of the drug for prevention, and promotes the preventive use of people with poor vaccine response
    .
     
      Zhong Nanshan, academician of the Chinese Academy of Engineering: If it (medicine) costs very high, prevention is not realistic
    .
    But at least until now, I think we should see some poor immune function (the crowd), such as whether it is heavier chronic heart disease, chronic obstructive pulmonary disease, liver disease, first with the antibody in advance, there may be good The preventive effect
    .
    Heart, heart, heart
     
      According to reports, these two drugs can be used in combination to treat mild and common adults and adolescents with new coronavirus infections who are accompanied by high risk factors for progression to severe
    .
    Are there any side effects after the drug is used? Academician Zhong Nanshan also gave the answer
    .
     
      On December 12, Tengshengbo Pharmaceutical issued an announcement.
    The data shows that the approved drugs are against Omi Keron and other widely concerned new coronavirus variants including Alpha, Beta, Gamma, Delta, Delta+, etc.
    Maintained its effectiveness
    .
    Zhang Qi, an assistant researcher at the School of Medicine of Tsinghua University, who participated in the research and development, said that there may be more mutations in the virus, but researchers are already prepared
    .
     
      Zhang Qi, assistant researcher at the School of Medicine of Tsinghua University: We have also felt some patterns, because the mutant strain is always mutating.
    We can’t say what Omi Keron will come out today, and what will come out tomorrow.
    We are always chasing after it.
    We have to To prepare in advance, we have been studying where the changes of mutant strains are to deal with possible mutations in the future
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.